Hartrampf Philipp E, Heinrich Marieke, Seitz Anna Katharina, Brumberg Joachim, Sokolakis Ioannis, Kalogirou Charis, Schirbel Andreas, Kübler Hubert, Buck Andreas K, Lapa Constantin, Krebs Markus
Department of Nuclear Medicine, University Hospital Würzburg, 97080 Würzburg, Germany.
Department of Urology and Paediatric Urology, University Hospital Würzburg, 97080 Würzburg, Germany.
J Clin Med. 2020 May 8;9(5):1390. doi: 10.3390/jcm9051390.
(1) Background: Prostate-specific membrane antigen (PSMA)-derived tumour volume (PSMA-TV) and total lesion PSMA (TL-PSMA) from PSMA PET/CT scans are promising biomarkers for assessing treatment response in prostate cancer (PCa). Currently, it is unclear whether different software tools for assessing PSMA-TV and TL-PSMA produce comparable results. (2) Methods: Ga-PSMA PET/CT scans from = 21 patients with castration-resistant PCa (CRPC) receiving chemotherapy were identified from our single-centre database. PSMA-TV and TL-PSMA were calculated with Syngo.via (Siemens) as well as the freely available Beth Israel plugin for FIJI (Fiji Is Just ImageJ) before and after chemotherapy. While statistical comparability was illustrated and quantified via Bland-Altman diagrams, the clinical agreement was estimated by matching PSMA-TV, TL-PSMA and relative changes of both variables during chemotherapy with changes in serum PSA (ΔPSA) and PERCIST (Positron Emission Response Criteria in Solid Tumors). (3) Results: Comparing absolute PSMA-TV and TL-PSMA as well as Bland-Altman plotting revealed a good statistical comparability of both software algorithms. For clinical agreement, classifying therapy response did not differ between PSMA-TV and TL-PSMA for both software solutions and showed highly positive correlations with BR. (4) Conclusions: due to the high levels of statistical and clinical agreement in our CRPC patient cohort undergoing taxane chemotherapy, comparing PSMA-TV and TL-PSMA determined by Syngo.via and FIJI appears feasible.
(1) 背景：前列腺特异性膜抗原（PSMA）衍生的肿瘤体积（PSMA-TV）和PSMA正电子发射断层扫描/计算机断层扫描（PSMA PET/CT）的总病变PSMA（TL-PSMA）是评估前列腺癌（PCa）治疗反应的有前景的生物标志物。目前，尚不清楚用于评估PSMA-TV和TL-PSMA的不同软件工具是否能产生可比的结果。(2) 方法：从我们的单中心数据库中识别出21例接受化疗的去势抵抗性PCa（CRPC）患者的镓-PSMA PET/CT扫描图像。在化疗前后，使用Syngo.via（西门子）以及免费的用于FIJI（Fiji Is Just ImageJ）的贝斯以色列插件计算PSMA-TV和TL-PSMA。通过布兰德-奥特曼图说明并量化统计可比性，通过将化疗期间PSMA-TV、TL-PSMA以及这两个变量的相对变化与血清前列腺特异抗原（ΔPSA）和实体瘤正电子发射反应标准（PERCIST）的变化进行匹配来估计临床一致性。(3) 结果：比较绝对PSMA-TV和TL-PSMA以及布兰德-奥特曼绘图显示两种软件算法具有良好的统计可比性。对于临床一致性，两种软件解决方案在PSMA-TV和TL-PSMA之间对治疗反应的分类没有差异，并且与BR显示出高度正相关。(4) 结论：由于在我们接受紫杉烷化疗的CRPC患者队列中统计和临床一致性水平较高，比较由Syngo.via和FIJI确定的PSMA-TV和TL-PSMA似乎是可行的。
